Sam Brusco, Associate Editor05.23.23
Biotronik has received U.S. Food and Drug Administration (FDA) approval for its new BIOMONITOR IV implantable cardiac monitor (ICM). The device, debuted at the Heart Rhythm Society Congress 2023, features the company’s advanced, artificial intelligence (AI)-powered SmartECG algorithm.
BIOMONITOR IV’s SmartECG includes advanced algorithms to reduce 86% of all false positives, while preserving 98% of true episodes, according to the company. The tech can offer more detection accuracy, reducing false positive alerts and helping to achieve timely and accurate diagnosis of certain heart conditions.
BIOMONITOR IV is also the first ICM, according to Biotronik, to discriminate between premature atrial contractions (PACs) and premature ventricular contractions (PVCs). This advances remote cardiac monitoring by offering reliable PAC and PVC trends for risk stratification and diagnosis.
Other new features include patient-initiated on-demand transmissions, customizable indication-based alert templates, and remote filtering options. These were engineered to streamline the review process so healthcare professionals can manage patients more effectively.
“Our customers have expressed the desire for an innovative device that reduces false positive alerts to provide more efficient care for their patients. With BIOMONITOR IV, we are able to meet the needs of our customers and patients,” David Hayes, MD, chief medical officer at Biotronik Inc. told the press. “BIOMONITOR IV represents our commitment to advancing the field of cardiac diagnosis and allowing clinicians to focus on what’s most important—the patient.”
BIOMONITOR IV’s SmartECG includes advanced algorithms to reduce 86% of all false positives, while preserving 98% of true episodes, according to the company. The tech can offer more detection accuracy, reducing false positive alerts and helping to achieve timely and accurate diagnosis of certain heart conditions.
BIOMONITOR IV is also the first ICM, according to Biotronik, to discriminate between premature atrial contractions (PACs) and premature ventricular contractions (PVCs). This advances remote cardiac monitoring by offering reliable PAC and PVC trends for risk stratification and diagnosis.
Other new features include patient-initiated on-demand transmissions, customizable indication-based alert templates, and remote filtering options. These were engineered to streamline the review process so healthcare professionals can manage patients more effectively.
“Our customers have expressed the desire for an innovative device that reduces false positive alerts to provide more efficient care for their patients. With BIOMONITOR IV, we are able to meet the needs of our customers and patients,” David Hayes, MD, chief medical officer at Biotronik Inc. told the press. “BIOMONITOR IV represents our commitment to advancing the field of cardiac diagnosis and allowing clinicians to focus on what’s most important—the patient.”